Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac and Edinburgh Instruments have announced that AstraZeneca will carry out an evaluation of the newly launched Flexyte protein kinase assay platform.
Subscribe to our email newsletter
During the evaluation period, AstraZeneca will assess the performance of the Flexyte platform in its laboratories against specific targets of interest.
Stephen Barr, president and managing director of Almac Science, said: “We are delighted that AstraZeneca have shown this level of interest in our proprietal protein kinase assay platform. Their evaluation of Flexyte indicates the potential of fluorescence lifetime as a reporting modality for kinase assays.”
Flexyte assays harness the potential of fluorescence lifetime and applies it to the process of assaying kinase activity and, as Almac Sciences said, marks a successful collaboration between Almac Sciences, Edinburgh Instruments and Dundee University.